Background The lastly identified claudin-low (CL) subtype of breast cancer (BC) remains
poorly described as compared to the other molecular subtypes. We provide a comprehensive …

There is increasing evidence that breast tumors are organized in a hierarchy, with a subpopulation
of tumorigenic cancer cells, the cancer stem cells (CSCs), which sustain tumor growth…

Introduction ECRG4/C2ORF40 is a potential tumor suppressor gene (TSG) recently identified
in esophageal carcinoma. Its expression, gene copy number and prognostic value have …

The oncogenic events involved in breast implant–associated anaplastic large cell lymphoma
(BI-ALCL) remain elusive. To clarify this point, we have characterized the genomic …

Breast cancers (BCs) of the luminal B subtype are estrogen receptor-positive (ER+), highly
proliferative, resistant to standard therapies and have a poor prognosis. To better understand …

Personalized medicine uses genomic information for selecting therapy in patients with
metastatic cancer. An issue is the optimal tissue source (primary tumor or metastasis) for testing. …

In some types of cancer, telomere length is maintained by the alternative lengthening of
telomeres (ALT) mechanism. In many ALT cancers, the α‐thalassemia/mental retardation …

Despite recent advances in acute myeloid leukemia (AML) molecular characterization and
targeted therapies, a majority of AML cases still lack therapeutically actionable targets. In 127 …

ESPL1/separase is a putative oncogene of luminal B breast cancers. Histoclinical
correlations of its expression have never been explored in large series of breast tumors, and …

Background The benefit of precision medicine based on relatively limited gene sets and
often-archived samples remains unproven. PERMED-01 (NCT02342158) was a prospective …